Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

2.19%

Insider Ownership

0.00%

Institutional Own.

56.90%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYVGART Hytrulo (SC Efgartigimod) Details
Myasthenia gravis, Autoimmune disease

Approved

Quarterly sales

Efgartigimod Details
Primary immune thrombocytopenia

Phase 3

Update

VYVGART Hytrulo (Efgartigimod) Details
Chronic inflammatory disorder

Phase 3

Update

Empasiprubart Details
Neuropathy, Neuromuscular disease, Multifocal motorneuropathy

Phase 2

Data readout

Efgartigimod Details
Sjögren-Larsson Syndrome

Phase 2

Data readout

Efgartigimod Details
Post-COVID Postural Orthostatic Tachycardia Syndrome

Phase 2

Data readout

Empasiprubart Details
Dermatomyositis

Phase 2

Initiation

Empasiprubart Details
Delayed graft function

Phase 2

Initiation

ARGX -119 Details
Amyotrophic lateral sclerosis, Congenital myasthenic syndrome

Phase 1

Data readout

Efgartigimod Details
Mucosal Pemphigus Vulgaris

Failed

Discontinued